Unknown

Dataset Information

0

Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by Mycobacterium bovis Bacille Calmette-Guerin.


ABSTRACT: Mycobacterium bovis bacille Calmette-Guérin (BCG) is listed as an intralesional (IL) therapeutic option for inoperable stage III in-transit melanoma in the National Comprehensive Cancer Network Guidelines. Although the mechanism is unknown, others have reported up to 50% regression of injected lesions, and 17% regression of uninjected lesions in immunocompetent patients after direct injection of BCG into metastatic melanoma lesions in the skin. BCG and other mycobacteria express ligands capable of stimulating the ?9?2 T cells. Therefore, we hypothesized that ?9?2 T cells play a role in promoting BCG-mediated antitumor immunity in patients treated with IL-BCG for in-transit cutaneous melanoma metastases. Indeed, we found ?9?2 T cell infiltration in melanoma skin lesions during the course of IL-BCG treatment. Gene expression analysis revealed that BCG injection elicits the expression of a vast array of chemokines in tumor lesions, including strong expression of CXCL9, 10, and 11, a set of chemokines that attract T cells expressing the CXCR3 chemokine receptor. In corroboration with our hypothesis, approximately 85% of ?? T cells express high levels of CXCR3 on their surface. Importantly, the injected tumor lesions also express genes whose protein products are the antigenic ligands for ?? T cells (BTN3A1 and MICB), and the cytokines that are the typical products of activated ?? T cells. Interestingly, we also found that ?? T cells infiltrate the regressed lesions that did not receive BCG injections. Our study suggests that ?9?2 T cells may contribute to melanoma regression induced by IL-BCG treatment.

SUBMITTER: Yang J 

PROVIDER: S-EPMC5380679 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by <i>Mycobacterium bovis</i> Bacille Calmette-Guérin.

Yang Junbao J   Jones Maris S MS   Ramos Romela Irene RI   Chan Alfred A AA   Lee Agnes F AF   Foshag Leland J LJ   Sieling Peter A PA   Faries Mark B MB   Lee Delphine J DJ  

Frontiers in oncology 20170405


<i>Mycobacterium bovis</i> bacille Calmette-Guérin (BCG) is listed as an intralesional (IL) therapeutic option for inoperable stage III in-transit melanoma in the National Comprehensive Cancer Network Guidelines. Although the mechanism is unknown, others have reported up to 50% regression of injected lesions, and 17% regression of uninjected lesions in immunocompetent patients after direct injection of BCG into metastatic melanoma lesions in the skin. BCG and other mycobacteria express ligands c  ...[more]

Similar Datasets

| S-EPMC2808266 | biostudies-literature
| S-EPMC7775372 | biostudies-literature
| S-EPMC3295601 | biostudies-literature
| S-EPMC5056730 | biostudies-literature
| S-EPMC6264175 | biostudies-literature
| S-EPMC5536119 | biostudies-literature
| S-EPMC4465024 | biostudies-literature
| S-EPMC3146779 | biostudies-literature
| S-EPMC3764428 | biostudies-literature
| S-EPMC7050990 | biostudies-literature